The MHRA, or Medicines and Healthcare products Regulatory Agency, is the UK government agency that regulates medicines, vaccines, and medical devices. Its job is to make sure these products meet appropriate standards of safety, quality, and effectiveness before they reach patients in the UK.
The MHRA continues to monitor medicines and devices after they become available to the public. This includes overseeing how products are supplied, checking how they work in real-world use, and investigating possible safety concerns.
The MHRA also helps to support the development of new treatments by working with researchers, NHS organisations, and pharmaceutical companies. This work aims to make safe and effective medicines available to patients more quickly.
The agency runs the Yellow Card Scheme, which allows patients, carers, and healthcare professionals to report suspected side effects, adverse drug reactions, and safety problems with medicines, vaccines, and medical devices.
MHRA stands for the Medicines and Healthcare products Regulatory Agency. It is the UK government agency responsible for regulating medicines, vaccines, and medical devices.
The MHRA is the UK government agency that regulates medicines and medical devices. It checks that these products are safe, effective, and of good quality, and continues to monitor them after they reach patients. The MHRA is an executive agency of the UK Department of Health and Social Care.
The MHRA’s main responsibilities include:
Supporting research and innovation in healthcare
No. Most cannabis-based medicinal products prescribed in the UK are unlicensed medicines and have not received MHRA marketing authorisation.
An unlicensed medicine is not illegal. It means the product has not been through the full MHRA licensing process for a specific medical condition. Specialist doctors on the General Medical Council’s Specialist Register can still prescribe unlicensed cannabis-based medicines when they believe it is clinically appropriate for an individual patient.
A small number of cannabis-based medicines have been licensed by the MHRA for specific conditions, including:
The MHRA and the GMC have very different roles in the UK healthcare system: